Co-administration of Staphylococcus aures Fibronectin Binding Protein A N1-3 region and Lipoteichoic acid antigen mixture enhance antibody response in BALB/c mice

Staphylococcus aureus (S. aureus) is a prevalent human pathogen responsible for a wide array of infections, ranging from minor skin issues to severe systemic diseases. The rise of antibiotic-resistant S. aureus strains has underscored the urgent need for effective vaccines. As S. aureus pathogens utilize surface antigens to colonize and infect host cells, targeting these antigens could prove beneficial for vaccine development.

In a recent study, researchers investigated the potential of two key S. aureus surface antigens - fibronectin-binding protein A (FnBPA) and lipoteichoic acid (LTA) as vaccine candidates.

A recombinant fusion protein (r-FR) was developed by attaching the N-terminal segment of FnBPA to rhizavidin and expressing it in Escherichia coli. This protein was then combined with LTA that had been biotinylated to create an antigen mixture called r-FR+LTA. This mixture, along with r-FR alone, was administered to BALB/c mice via emulsification in Freunds adjuvant.

The results revealed that mice receiving the r-FR+LTA mixture exhibited a robust antibody response, exhibited more potent bacterial growth inhibition in vitro, and showed improved survival rates following a lethal S. aureus challenge compared to mice that received r-FR alone. These findings indicate that combining surface antigens like FnBPA with LTA in a multi-antigen vaccine strategy may enhance the protective efficacy against S. aureus infections.